Compare Biogen Inc (BIIB) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs J M Smucker Co — how do they compare? Biogen Inc trades at $191.25 (market cap $28.34B), while J M Smucker Co trades at $108.33 (market cap $11.63B). The key difference: Biogen Inc is far larger — about 2.4× J M Smucker Co's market cap, and J M Smucker Co pays a 4.04% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | SJM | |
|---|---|---|
Market Cap | $28.34B | $11.63B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $117.05 |
52-Week Low | $122.68 | $89.53 |
Enterprise Value | $30.62B | $18.66B |
Dividend Yield | — | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
SJM trades at $110.53, down 0.96% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed earnings with Q4 2026 beating estimates but Q3 2025 missing, alongside a net loss of $1.23 billion in 2025. Recent news highlights Uncrustables as a growth driver, while the Twinkie acquisition faces challenges. Cash flow improved to a net positive $7.90 million in 2025, though debt-to-asset ratio rose to 43.71%.
Outlook is cautious with analyst consensus at Buy (51.61%) and a $123.18 price target, but risks include high debt, margin pressure, and FY2027 sales guidance down 3-4%. The dividend yield of about 1% offers income, but growth depends on coffee margin recovery and Uncrustables expansion amid competitive headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
